Caseware UK (AP4) 2023.0.135 2023.0.135 2023-06-302023-06-3012022-07-01truefalse1trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 09097962 2022-07-01 2023-06-30 09097962 2021-07-01 2022-06-30 09097962 2023-06-30 09097962 2022-06-30 09097962 c:Director1 2022-07-01 2023-06-30 09097962 d:CurrentFinancialInstruments 2023-06-30 09097962 d:CurrentFinancialInstruments 2022-06-30 09097962 d:CurrentFinancialInstruments d:WithinOneYear 2023-06-30 09097962 d:CurrentFinancialInstruments d:WithinOneYear 2022-06-30 09097962 d:ShareCapital 2023-06-30 09097962 d:ShareCapital 2022-06-30 09097962 d:RetainedEarningsAccumulatedLosses 2023-06-30 09097962 d:RetainedEarningsAccumulatedLosses 2022-06-30 09097962 c:OrdinaryShareClass1 2022-07-01 2023-06-30 09097962 c:OrdinaryShareClass1 2023-06-30 09097962 c:FRS102 2022-07-01 2023-06-30 09097962 c:AuditExempt-NoAccountantsReport 2022-07-01 2023-06-30 09097962 c:FullAccounts 2022-07-01 2023-06-30 09097962 c:PrivateLimitedCompanyLtd 2022-07-01 2023-06-30 09097962 6 2022-07-01 2023-06-30 xbrli:shares iso4217:GBP xbrli:pure
Registered number: 09097962














MEDILOGYCAL LIMITED

 
UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2023

 
MEDILOGYCAL LIMITED
 

CONTENTS



Page
Balance Sheet
 
1 - 2
Notes to the Financial Statements
 
3 - 5


 
MEDILOGYCAL LIMITED
REGISTERED NUMBER:09097962

BALANCE SHEET
AS AT 30 JUNE 2023

2023
2022
Note
£
£

Fixed assets
  

Investments
 4 
-
3,580,346

  
-
3,580,346

Current assets
  

Debtors: amounts falling due within one year
 5 
143,934
732,377

Cash at bank and in hand
 6 
-
13,274

  
143,934
745,651

Creditors: amounts falling due within one year
 7 
-
(4,180,204)

Net current assets/(liabilities)
  
 
 
143,934
 
 
(3,434,553)

Total assets less current liabilities
  
143,934
145,793

  

Net assets
  
143,934
145,793


Capital and reserves
  

Called up share capital 
 8 
100
100

Profit and loss account
  
143,834
145,693

  
143,934
145,793


1

 
MEDILOGYCAL LIMITED
REGISTERED NUMBER:09097962
    
BALANCE SHEET (CONTINUED)
AS AT 30 JUNE 2023

The director considers that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 18 April 2024.




G Dhillon
Director

The notes on pages 3 to 5 form part of these financial statements.

2

 
MEDILOGYCAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023

1.


General information

Medilogycal Limited is a private company, limited by shares, domiciled in England and Wales, registration number 09097962. The registered office address is Elsley Court, 20-22 Great Titchfield Street, London, W1W 8BE.
The principle activity of the company continued to be that of a holding company for a pharmaceutical company.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The company's functional and presentational currency is pound sterling.

The following principal accounting policies have been applied:

 
2.2

Exemption from preparing consolidated financial statements

The company, and the Group headed by it, qualify as small as set out in section 383 of the Companies Act 2006 and the parent and Group are considered eligible for the exemption to prepare consolidated accounts.

 
2.3

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.4

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.5

 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

 
2.6

 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

 Financial instruments

The company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.


3.


Employees

The average monthly number of employees, including directors, during the year was 1 (2022 - 1).

3

 
MEDILOGYCAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023

4.


Fixed asset investments





Investments in subsidiary companies

£





At 1 July 2022
3,580,346


Transfers intra group
(3,580,346)



At 30 June 2023
-






Net book value



At 30 June 2023
-



At 30 June 2022
3,580,346


5.


Debtors

2023
2022
£
£


Amounts owed by group undertakings
143,934
100

Other debtors
-
570

Prepayments and accrued income
-
731,707

143,934
732,377



6.


Cash and cash equivalents

2023
2022
£
£

Cash at bank
-
13,274



7.


Creditors: Amounts falling due within one year

2023
2022
£
£

Amounts owed to group undertakings
-
1,946,837

Corporation tax
-
301

Other creditors
-
2,230,851

Accruals
-
2,215

-
4,180,204


4

 
MEDILOGYCAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023

8.


Share capital

2023
2022
£
£
Allotted, called up and fully paid



100 Ordinary shares of £1.00 each
100
100



9.


Related party transactions

No disclosure has been made of transactions with other wholly owned group companies in accordance with FRS 102 section 1A paragraph 1AC.35.

 
5